162 related articles for article (PubMed ID: 31225959)
1. HPV Testing for Cervical Cancer in Romania: High-Risk HPV Prevalence among Ethnic Subpopulations and Regions.
Ilisiu MB; Hashim D; Andreassen T; Støer NC; Nicula F; Weiderpass E
Ann Glob Health; 2019 Jun; 85(1):. PubMed ID: 31225959
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of positive screening test results and agreement between cytology and human papillomavirus testing in primary cervical cancer screening in North-Western Romania.
Şuteu O; Blaga ML; Nygård M; Leinonen MK; Nicula F; Păiş R; Coza D; Cadariu PA; Melnic A; Andreassen T; Hashim D; Weiderpass E
Eur J Cancer Prev; 2020 Mar; 29(2):141-148. PubMed ID: 31033568
[TBL] [Abstract][Full Text] [Related]
3. HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows.
Huijsmans CJ; Geurts-Giele WR; Leeijen C; Hazenberg HL; van Beek J; de Wild C; van der Linden JC; van den Brule AJ
BMC Cancer; 2016 Nov; 16(1):922. PubMed ID: 27894291
[TBL] [Abstract][Full Text] [Related]
4. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of high-risk human papillomavirus types and cervical squamous intraepithelial lesions in women over 30 years of age in St. Petersburg, Russia.
Shipitsyna E; Zolotoverkhaya E; Kuevda D; Nasonova V; Romanyuk T; Khachaturyan A; Orlova O; Abashova E; Kostyuchek I; Shipulina O; Anttila A; Savicheva A
Cancer Epidemiol; 2011 Apr; 35(2):160-4. PubMed ID: 20884314
[TBL] [Abstract][Full Text] [Related]
6. Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study.
Derchain SF; Sarian LO; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo RC; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
J Med Screen; 2008; 15(2):97-104. PubMed ID: 18573778
[TBL] [Abstract][Full Text] [Related]
7. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
8. High-risk human papillomaviruses distribution in Romanian women with negative cytology.
Plesa A; Socolov D; Huica I; Botezatu A; Iancu IV; Ungureanu C; Teleman S; Albulescu A; Fudulu A; Anton G
J Infect Dev Ctries; 2019 Apr; 13(4):326-333. PubMed ID: 32045377
[TBL] [Abstract][Full Text] [Related]
9. Very low human Papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests.
Zhao C; Elishaev E; Yuan KH; Yu J; Austin RM
Cancer; 2007 Oct; 111(5):292-7. PubMed ID: 17879368
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of abnormal cervical smears in a hospital cohort of French women beyond the upper age limit screening program.
Luquain A; Belglaiaa E; Guenat D; Vrecko S; Riethmuller D; Valmary-Degano S; Bedgedjian I; Chouham S; Prétet JL; Mougin C
Prev Med; 2015 Dec; 81():157-62. PubMed ID: 26348451
[TBL] [Abstract][Full Text] [Related]
11. Changes in High-Risk HPV Infection Prevalence and Associated Factors in Selected Rural Areas of China: A Multicenter Population-Based Study.
Yu YQ; Jiang MY; Dang L; Feng RM; Bangura MS; Chen W; Qiao YL
Front Med (Lausanne); 2022; 9():911367. PubMed ID: 35903319
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Associated Factors of Abnormal Cervical Cytology and HighRisk HPV DNA among Bangkok Metropolitan Women.
Tangjitgamol S; Kantathavorn N; Kittisiam T; Chaowawanit W; Phoolcharoen N; Manusirivithaya S; Khunnarong J; Srijaipracharoen S; Saeloo S; Krongthong W; Supawattanabodee B; Thavaramara T; Pataradool K
Asian Pac J Cancer Prev; 2016; 17(7):3147-53. PubMed ID: 27509943
[TBL] [Abstract][Full Text] [Related]
13. Screening for persistent high-risk HPV infections may be a valuable screening method for young women; A retrospective cohort study.
Ebisch RMF; Ketelaars PJW; van der Sanden WMH; Schmeink CE; Lenselink CH; Siebers AG; Massuger LFAG; Melchers WJG; Bekkers RLM
PLoS One; 2018; 13(10):e0206219. PubMed ID: 30356297
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
15. The Risk Factors for Cervical Cytological Abnormalities Among Women Infected With Non-16/18 High-Risk Human Papillomavirus: Cross-sectional Study.
Xiao T; Ou CQ; Yang J; Wang C; Yang M; Yu T; Shen L; Xu X; Xing H
JMIR Public Health Surveill; 2022 Dec; 8(12):e38628. PubMed ID: 36480259
[TBL] [Abstract][Full Text] [Related]
16. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.
Zhang J; Zhao Y; Dai Y; Dang L; Ma L; Yang C; Li Y; Kong L; Wei L; Zhang S; Liu J; Xi M; Chen L; Duan X; Xiao Q; Abulizi G; Zhang G; Hong Y; Gao X; Zhou Q; Xie X; Li L; Niyazi M; Zhang Z; Tuo J; Ding Y; Si M; Chen F; Song L; Qiao Y; Lang J
JAMA Oncol; 2021 Feb; 7(2):263-270. PubMed ID: 33377903
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with high-risk human papillomavirus infection and high-grade cervical neoplasia: A population-based study in Paraguay.
Kasamatsu E; Rodríguez Riveros MI; Soilan AM; Ortega M; Mongelós P; Páez M; Castro A; Cristaldo C; Báez FR; Centurión CC; Vester J; Barrios H; Villalba G; Amarilla ML; Giménez G; Caubere E; Hernández ML; Baena A; Almonte M; Herrero R; Mendoza LP;
PLoS One; 2019; 14(6):e0218016. PubMed ID: 31246959
[TBL] [Abstract][Full Text] [Related]
19. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.
Tao X; Griffith CC; Zhou X; Wang Z; Yan Y; Li Z; Zhao C
Cancer Cytopathol; 2015 Jul; 123(7):421-7. PubMed ID: 25955972
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
